Yahoo! Finance: Dialectic Therapeutics Announces First-in-Human Dose in Phase 1 Clinical Trial Evaluating DT2216
Renowned cancer centers participating in the trial include the Mays Cancer Center at UT Health San Antonio, Mary Crowley Cancer Research in Dallas, Texas and The Lurie Cancer Center at Northwestern University in Chicago, Illinois.
Based in Dallas, Texas, Dialectic has research partners and facilities at UT Health San Antonio and University of Florida Health. Biotech venture investors John D. Harkey, Jr. and Dr. David Genecov capitalized the Company in 2018 and are co-founders along with Dr. Robert Hromas, Dean of the Long School of Medicine at UT Health San Antonio, Dr. Daohong Zhou at University of Florida Health Cancer Center, and Dr. Guangrong Zheng at University of Florida College of Pharmacy.